Noxopharm Ltd (ASX: NOX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Noxopharm Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$17.82 million
P/E Ratio
32.89
Dividend Yield
0.00%
Shares Outstanding
292.24 million
Earnings per share
-0.019
Dividend per share
N/A
Year To Date Return
-37.63%
Earnings Yield
3.04%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Noxopharm Ltd (ASX: NOX)
Latest News
Healthcare Shares
This ASX healthcare share is surging 17% on a new FDA ruling
Earnings Results
Clinical trials not enough to stop Noxopharm (ASX:NOX) shares' 5% plunge on Monday
Share Market News
The Noxopharm (ASX:NOX) share price is jumping 6% after announcing a new CEO
Healthcare Shares
Here's why the Noxopharm (ASX: NOX) share price leapt 7% today
Share Gainers
Why is the Noxopharm (ASX:NOX) share price up 4% on Monday?
Share Gainers
Noxopharm (ASX:NOX) share price jumps 13% on COVID treatment update
Healthcare Shares
The Noxopharm (ASX:NOX) share price is soaring 7%
Healthcare Shares
Noxopharm (ASX:NOX) share price edges lower after clinical trial update
Share Gainers
Why the Noxopharm (ASX:NOX) share price is charging higher again
Share Market News
Why the Noxopharm share price rocketed 22% today
Healthcare Shares
Here's why the Noxopharm (ASX:NOX) share price is flying 16% today
Share Gainers
Here's why the Noxopharm (ASX:NOX) share price is surging 6% higher
1❯
NOX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Noxopharm Ltd
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
NOX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Mar 2026 | $0.06 | $0.00 | 0.00% | 168,657 | $0.06 | $0.06 | $0.06 |
| 27 Mar 2026 | $0.06 | $0.00 | 0.00% | 83,095 | $0.06 | $0.06 | $0.06 |
| 26 Mar 2026 | $0.06 | $-0.01 | -15.63% | 42,363 | $0.06 | $0.06 | $0.06 |
| 25 Mar 2026 | $0.06 | $0.00 | 0.00% | 696,865 | $0.06 | $0.06 | $0.06 |
| 23 Mar 2026 | $0.06 | $0.00 | 0.00% | 10,000 | $0.06 | $0.06 | $0.06 |
| 19 Mar 2026 | $0.06 | $0.00 | 0.00% | 60,005 | $0.06 | $0.07 | $0.06 |
| 18 Mar 2026 | $0.06 | $0.00 | 0.00% | 3,000 | $0.06 | $0.06 | $0.06 |
| 17 Mar 2026 | $0.06 | $0.00 | 0.00% | 47,772 | $0.06 | $0.06 | $0.06 |
| 16 Mar 2026 | $0.06 | $0.00 | 0.00% | 71,314 | $0.06 | $0.06 | $0.06 |
| 13 Mar 2026 | $0.06 | $0.00 | 0.00% | 31,942 | $0.06 | $0.06 | $0.06 |
| 12 Mar 2026 | $0.06 | $0.00 | 0.00% | 114,146 | $0.06 | $0.06 | $0.06 |
| 10 Mar 2026 | $0.06 | $0.00 | 0.00% | 6,994 | $0.06 | $0.06 | $0.06 |
| 09 Mar 2026 | $0.06 | $0.00 | 0.00% | 42,381 | $0.06 | $0.06 | $0.06 |
| 06 Mar 2026 | $0.06 | $0.00 | 0.00% | 12,282 | $0.06 | $0.06 | $0.06 |
| 05 Mar 2026 | $0.07 | $0.00 | 0.00% | 70,057 | $0.06 | $0.07 | $0.06 |
| 04 Mar 2026 | $0.06 | $-0.01 | -14.71% | 46,314 | $0.07 | $0.07 | $0.06 |
| 03 Mar 2026 | $0.07 | $0.00 | 0.00% | 11,094 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Dec 2025 | Frederick (Fred) Bart | Issued | 1,250,000 | $1,250,000 |
Issue of securities. 1,250,000 convertible notes
|
| 12 Dec 2025 | Frederick (Fred) Bart | Issued | 250,000 | $24,750 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Frederick (Fred) Bart | Non-Executive DirectorNon-Executive Chairman | May 2020 |
Mr Bart was appointed the Managing Director of Textile Industries Australia. He established and chairs a number of private companies under the umbrella of the Bart Group which covered hotels, retail, commercial and residential land development and technologies which still continue to operate. He became Director and majority shareholder of Immunovative Therapies Limited, a private Israeli company involved in the manufacture of vaccines for the treatment of certain forms of cancer. The Company has undertaken trials in both colorectal and liver cancers. He is Member of Risk Committee.
|
| Mr Peter Ashley Marks | Non-Executive DirectorNon-Executive Deputy Chairman | Mar 2016 |
Mr Marks has over 35 years of experience in corporate advisory and investment banking. Over the course of his career, he has specialised in capital raising IPOs, cross border capital raisings, M&A transactions, corporate underwriting and venture capital transactions for companies based in Australia, the US and Israel. He has been involved in a broad range of transactions with a special focus in the life sciences, biotechnology, medical technology and high tech as well as the mining sector. He has served as both an Executive and Non Executive Director of a number of different entities, many of which have been listed on the ASX, Nasdaq and AIM markets. He is Chair of the Risk Committee.
|
| Mr Boris Patkin | Non-Executive Director | Mar 2020 |
Mr Patkin brings market knowledge, thorough research and years of experience in investment markets and business consulting. He has an indepth understanding of industry trends and has valuable insight into domestic and international markets. He specialises in the reconstruction of companies, investments and in international trade and is also an experienced business consultant in the medical and disruptive technology arena. He is a senior advisor with Morgans Financial Ltd. He is Member of the Risk Committee.
|
| Dr Gisela Mautner | Chief Executive OfficerManaging Director | Feb 2022 |
Dr Mautner has more than 20 years of leadership experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across multiple therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.
|
| Mr David James Franks | Company Secretary | Jan 2017 |
-
|
| David James Franks | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Milligene Pty Ltd (The Ge and Pr Kelly Family A/C) | 34,249,106 | 11.72% |
| Mrs Eleanore Goodridge | 13,050,000 | 4.47% |
| Citicorp Nominees Pty Ltd | 10,992,174 | 3.76% |
| Link Traders (Aust) Pty Ltd | 10,586,522 | 3.62% |
| Mr Fred Bart | 7,507,813 | 2.57% |
| Rgt Capital Fund No 5 (Noxo) Pty Ltd | 6,500,333 | 2.22% |
| Jamber Investments Pty Ltd (The Amber Schwarz Fam A/C) | 4,252,761 | 1.46% |
| Rhlc Pty Limited (Rhlc S/F A/C) | 3,000,000 | 1.03% |
| Mr Lizhong Yu | 2,918,000 | 1.00% |
| Lawsam Pty Ltd (Gelski Family No 2 A/C) | 2,686,376 | 0.92% |
| Mr Robert Thomas Lin | 2,500,000 | 0.86% |
| Ogen Nominees Pty Ltd | 2,200,000 | 0.75% |
| Mr Michael Shabat & Ms Meital Hana Shabat (M&M Shabat Super Fund A/C) | 2,000,000 | 0.68% |
| Citicorp Nominees Pty Limited (120296 Infitude A/C) | 1,948,438 | 0.67% |
| Mrs Sophie Ethel Gelski | 1,942,424 | 0.66% |
| Helium Management Pty Ltd (Helium S/F A/C) | 1,751,246 | 0.60% |
| Berne No 132 Nominess Pty Ltd (331898 A/C) | 1,660,357 | 0.57% |
| Halcommunications Power Incorporated (Aust) Pty Ltd | 1,600,000 | 0.55% |
| Mr Clarke James Roycroft & Mrs Judith Ann Roycroft (C J Roycroft Family A/C) | 1,555,000 | 0.53% |
| Mr James John Bart | 1,525,755 | 0.52% |